A Phase 3, 2-Part, Randomized, Double-Blind,Placebo-Cont

  • Regelmann, Warren E (PI)

Project: Research project

Project Details


A Phase 3, 2-Part, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects Aged 6 to 11 Years with Cystic Fibrosisand the G551D Mutation
Effective start/end date10/8/099/30/13


  • Vertex Pharmaceuticals Incorporated

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.